Caribou Biosciences is a clinical-stage biopharmaceutical company based in Berkeley, CA, specializing in the development of genome-edited allogeneic cell therapies for severe human diseases. Their cutting-edge CRISPR genome-editing technology allows for precise and specific modifications to the genome, enabling complex gene knockout and insertion while maintaining genomic integrity.
With a focus on off-the-shelf cell therapies, Caribou Biosciences aims to address the limitations of currently approved therapies by developing allogeneic CAR-T and CAR-NK cell therapies from healthy donor cells. By applying their chRDNA technology and genome-editing strategies, they are working towards developing armored allogeneic cell therapies that have the potential to enhance antitumor activity, making them a leader in the CRISPR field.
Generated from the website